Most pharmaceutical teams still treat HTA evidence planning as a post-approval activity. In the EU of 2026, that approach is no longer viable. Since 12 January 2025, the Joint Clinical Assessment has been running in parallel with the EMA regulatory review, not after it. [1] For any oncology or ATMP product entering Phase III today, the JCA dossier deadline is anchored to the date of EMA submission. There is no post-approval buffer. The window to build credible, structured evidence is Phase II, and it is closing faster than most HEOR teams realise.
Pienomial's Knolens platform was designed for exactly this challenge. As a purpose-built market access analytics platform for the life sciences, Knolens enables HEOR and clinical teams to map evidence gaps, align comparator strategy, and build JCA-ready dossier architecture months before Phase III lock. Every output is traceable, every claim attributed, and the entire evidence base is kept current as the landscape evolves. This post walks through the practical playbook that HEOR teams are using in 2026.[6]
1. What EU JCA Changes for Pharma Evidence Teams
The EU Joint Clinical Assessment is mandatory for oncology and ATMP products from January 2025, expanding to orphan drugs in 2028 and all centrally authorised products in 2030. [1] Before JCA, each EU member state conducted its own national HTA assessment, each with a different methodology, different comparators, and different evidence standards. JCA replaces this with a single EU-level clinical effectiveness evaluation conducted jointly by EUnetHTA 21 bodies. The JCA dossier is not submitted after approval. It is submitted at the time of the EMA marketing authorisation application, giving manufacturers just 100 days from consolidated PICO scope communication to dossier submission. [2]
The practical consequence is significant. If your Phase III trial was not designed with JCA comparators and patient-relevant endpoints in mind, you arrive at submission with an evidence package that assessors will find structurally misaligned. ISPOR's 2026 to 2027 Top 10 HEOR Trends report places both AI and HTA cross-country collaboration in the top ten priorities for HEOR professionals globally, reflecting exactly this alignment pressure. [3]The clinical competitive intelligence required to prevent JCA misalignment must begin in Phase II, not Phase III.
2. The Five Evidence Pillars JCA Assessors Require
Pillar 1, Comparative Clinical Effectiveness: Head-to-head RCT data against the EU-defined standard of care is the gold standard. Where this is unavailable, an indirect treatment comparison is accepted with full network geometry documentation, common comparator justification, and heterogeneity assessment. ITC feasibility must be assessed before Phase III commits to its active comparator, not after data is collected.
Pillar 2, Patient-Relevant Endpoints: JCA methodology requires endpoints that patients and clinicians recognise as meaningful, including OS, quality of life, symptom burden, and functional status. Surrogate endpoints such as PFS or biomarker response require a documented, validated correlation to patient outcomes. If your Phase III primary endpoint is a surrogate in an indication where that correlation has not been established, your JCA submission carries a substantial evidential burden that no post-hoc analysis can fully repair.
Pillar 3, Pre-Specified Subgroup Analyses: JCA assessors routinely request subgroup breakdowns by age, disease severity, prior therapy, and biomarker status. Analyses not pre-specified in the protocol are classified as exploratory and carry minimal evidential weight. The subgroup requirement map must be built before the Phase III statistical analysis plan is finalised, drawing on what assessors have requested in analogous prior submissions.
Pillar 4, Indirect Treatment Comparisons: When direct head-to-head data against the EU standard of care is unavailable, JCA accepts adjusted indirect comparisons following EUnetHTA methodology. Network feasibility, heterogeneity quantification, and sensitivity analysis pre-specification must all be in place before Phase III is underway, because post-hoc ITC development is structurally weaker than a prospectively planned and pre-specified methodology.
Pillar 5, Real-World Evidence: Where trial populations are narrow, follow-up is limited, or the standard-of-care comparator is not available in an RCT context, JCA increasingly accepts RWE to supplement trial evidence. [2] The data sources, study design, and analysis plan for the RWE component must be identified and commissioned before Phase III completion, not searched retrospectively after approval.
3. Why Standard HEOR Evidence Planning Fails the JCA Test
The legacy HEOR workflow operates roughly as follows: complete Phase III, review the trial data, conduct a systematic literature review, build a cost-effectiveness model, and draft a dossier for each national HTA body sequentially. That model was built for a world where the submission clock started after EU approval and national assessments ran on separate, manageable timelines.
JCA has collapsed this structure entirely. Five specific failure modes emerge when the legacy workflow meets JCA requirements. First, the trial comparator may not match the JCA-defined EU standard of care. This gap cannot be addressed post-Phase III. Second, the primary endpoint may be a surrogate for which no validated patient-outcome correlation exists in the indication. Third, the protocol may not have pre-specified the subgroup analyses that JCA assessors will request, leaving only exploratory evidence. Fourth, ITC feasibility may not have been assessed, making it impossible to mount a credible indirect comparison. Fifth, no RWE data generation programme was commissioned early enough to produce data by submission.
Each failure is preventable. Each requires a structured evidence architecture decision made before Phase III lock, which is precisely where a pharma competitive intelligence strategy layer and a market access analytics platform working together create measurable commercial value.
4. How AI Accelerates JCA-Ready Evidence Architecture
Building JCA-ready evidence architecture manually is a multi-month exercise. Analysts search EUnetHTA submissions, EPAR documents, national HTA decisions, and ClinicalTrials.gov registrations for analogous assessments, map comparators, benchmark endpoints, and assess ITC feasibility. Even when completed efficiently, the output is a point-in-time document that becomes outdated as the competitive landscape evolves.
AI-powered enterprise intelligence platform capabilities compress this process from months to weeks. KnolAI, the research module of the Knolens platform, synthesises the full JCA evidence landscape, covering all published JCA assessments, EUnetHTA methodology guidance, analogous national HTA decisions, and competitor trial registrations. The output is a structured evidence gap map, traceable to specific source precedents, showing which evidence requirements the current trial design satisfies and which it does not.
The life sciences AI platform advantage is persistence. The evidence map updates continuously as new JCA assessments are published and as the competitive landscape shifts. A comparator that was appropriate at Phase II initiation may no longer reflect the EU standard of care by Month 18 if a new product has been approved in the indication. A static literature review cannot catch this shift. A living, governed knowledge layer does.
5. Knolens in Action: Phase II to JCA Submission
The Knolens-enabled JCA evidence planning workflow operates in five stages across the Phase II and pre-submission period.[6]
Stage 1, Month 1 to 2 of Phase II: KnolAI synthesises all published JCA assessments and EUnetHTA guidance for the indication. Output: a JCA evidence requirements brief covering the likely comparator set, endpoint patient-relevance precedents, subgroup analysis history, and ITC methodology expectations.
Stage 2, Month 3 to 4: KnolPersona, the expert simulation module, stress-tests the proposed Phase III protocol against the JCA requirements brief. Output: an assessor challenge report listing the most likely JCA criticisms of the current trial design, with specific evidence actions required to address each one before protocol lock.
Stage 3, Month 5 to 6: KnolComposer generates the evidence architecture specification, a structured document mapping each JCA evidence pillar to the planned Phase III data collection, with explicit gap analysis for RWE data generation and ITC feasibility.
Stage 4, Phase III execution: Knolens monitors the competitive landscape continuously, alerting the team if a new approval changes the JCA standard-of-care comparator or if new RWE evidence in the indication affects the evidence strategy.
Stage 5, Pre-submission: KnolComposer generates the JCA dossier clinical section with full provenance chains. Every clinical claim is traceable to a specific source, formatted to the JCA submission template. The timeline from query to JCA-ready evidence architecture is six weeks, compared to six or more months using traditional manual methods.
6. The Subgroup and ITC Challenge: Going Deeper
Two aspects of JCA evidence preparation consistently catch teams unprepared: subgroup pre-specification and ITC feasibility. Both require decisions before Phase III protocol lock, and both are areas where AI delivers the most direct analytical value.
For subgroup analyses, KnolAI queries prior JCA assessments in the same indication and mechanism class, extracting the specific subgroup breakdowns that assessors have historically requested. This list becomes a direct input to the Phase III statistical analysis plan, ensuring that the analyses JCA will ask for are confirmatory rather than exploratory. The difference in evidential weight is substantial. Confirmatory subgroup evidence supports a nuanced benefit rating. Exploratory evidence is flagged as hypothesis-generating and carries minimal weight in the final assessment.
For ITC, KnolAI constructs the treatment network geometry from all published trial data in the indication, identifies common comparators, quantifies heterogeneity signals, and assesses the feasibility of the specific adjusted comparison that the team will need at submission. A network feasibility report produced in Phase II gives the clinical statistics team the lead time to design the ITC methodology prospectively and document the pre-specification. This is the single most effective action a team can take to protect ITC's credibility in a JCA submission.
7. Scientific Advice Strategy: Preparing for EMA-HTA Parallel Consultation
EMA-HTA parallel scientific advice is the formal mechanism by which sponsors receive simultaneous feedback from EMA and JCA bodies before finalising Phase III design. It is the most powerful tool available for JCA evidence alignment, and it remains significantly underutilised across the industry.[4]
Sponsors who arrive at parallel advice with a half-formed evidence strategy receive generic methodological guidance. Those who arrive with a structured understanding of the JCA evidence landscape, including a mapped comparator analysis, an endpoint patient-relevance assessment, and an ITC feasibility report, receive specific, actionable feedback on the exact aspects of their Phase III design most likely to create JCA vulnerability.
The quality of feedback received is directly proportional to the quality of analysis brought to the meeting. A pharma scenario planning capability that simulates assessor responses to specific protocol design choices, combined with a competitive intelligence in healthcare layer that identifies what evidence has worked in analogous prior submissions, transforms parallel scientific advice from a generic consultation into a targeted protocol design workshop.
8. How Fast Can You Go Live with Knolens?
One of the most common questions HEOR and market access teams ask before adopting a new AI platform is: how long before we see real value? With Knolens, the answer is weeks, not months. Because Knolens ships as a fully built product with pre-loaded ontologies, pre-configured JCA evidence templates, and ready-to-run data pipelines, your team is not starting from a blank slate. The infrastructure is already there.
Teams typically go live with their first working use case, such as a JCA comparator landscape or an evidence gap map for an active indication, within six weeks of onboarding. There is no lengthy bespoke development phase. Knolens is configured to your indication and evidence priorities, not built from scratch.
Sprint 1, Weeks 1 to 2, Onboarding and first output: Knolens is connected to your indication scope. Pre-built JCA templates are activated. KnolAI runs the first evidence gap analysis against the EUnetHTA landscape. Your team receives the initial JCA evidence requirements brief. No IT build required.
Sprint 2, Weeks 3 to 4, Data source expansion: Additional data sources relevant to your indication, such as specific national HTA databases, disease registries, or internal clinical data, are added to the knowledge layer. The evidence map deepens automatically as new sources are ingested.
Sprint 3, Weeks 5 to 6, Workflow customisation: Alert thresholds, dossier output formats, and comparator monitoring scope are adjusted to match your team's workflow. KnolPersona is configured for your specific indication to simulate JCA assessor responses to your current protocol design.
From Sprint 3 onward, Knolens runs continuously as a living intelligence layer. New JCA assessments, competitor trial registrations, and RWE publications are ingested automatically. Your team receives structured alerts rather than spending time on manual source-checking. The total time from first conversation to first live value is typically under six weeks.[5]
9. Common Mistakes and How to Avoid Them
Six mistakes appear consistently across JCA evidence planning failures. Each is preventable with the right intelligence infrastructure.
Mistake 1: Treating JCA as a post-approval activity. The dossier is due at the EMA submission. There is no post-approval window for evidence preparation.
Mistake 2: Using the Phase III active comparator as the JCA comparator without prior verification. JCA defines its comparator set from the EU standard of care, which may differ from what the trial was designed against.
Mistake 3: Underestimating subgroup requirements. Build the subgroup requirement map from prior JCA assessments before Phase III statistical planning begins.
Mistake 4: Ignoring RWE data generation planning. Prospective studies commissioned at Phase III initiation generate two to three years of real-world follow-up data by submission. Retrospective searches of available databases rarely satisfy JCA assessors.
Mistake 5: Not requesting parallel scientific advice. This is a free mechanism to align with JCA assessors before Phase III design is locked, and the teams that use it produce structurally stronger dossiers.
Mistake 6: Relying on static evidence reviews. The JCA evidence landscape changes continuously. A one-time SLR does not catch the new approval that shifts the comparator or the new assessment that raises the endpoint standard.
Conclusion
The EU Joint Clinical Assessment has permanently moved the HEOR evidence clock forward by two to three years. The pharma teams achieving the strongest EU market access outcomes in 2026 are those that started building JCA-ready evidence architecture in Phase II, not those assembling a dossier after approval and discovering that the trial was designed against the wrong comparator.
Pienomial's Knolens platform provides the market access analytics platform and enterprise knowledge & AI memory platform infrastructure to make this shift practical. From Phase II evidence gap mapping through JCA dossier section generation, every output is traceable, every claim is attributed, and the evidence base stays current as the landscape evolves. For products currently in Phase II, the window to align Phase III design with JCA requirements is open now. CTA: Book a JCA Evidence Planning Consultation with Pienomial.
